hello
share versu et view refresh see stock act
appropri heel anoth good quarter recent past quarter stock trade flat despit strong result
think today stock reaction appropri abbott report organ sale growth driver continu usual suspect
libr alin well sever segment within devic manag also rais sale earn forecast year
call manag express confid outlook sustain growth note sustain state
earlier note hard view result anyth great quarter rate share overweight abbott growth like
remain peer rate make worthi premium valuat
call note first here coupl key takeaway wed like highlight
robert ford expect key leadership role com pani long tim read line
current ceo mile white said respons question manag chang success word think mile
signal robert ford pick next ceo mile white howev discuss time transit say give
time-frame comment occur smooth one said didnt think investor
nervou comment believ compani pois perform well across-the-board year come
see decad pretti robust growth
freestyl libr relativ eli soon anagem ent still expect icgm freestyl libr sale million quarter
report basi constant currenc basi manag note expect approv libr
rel soon express confid icgm design manag note continu build signific capac
support growth respons question whether could billion product time manag note last quarter
got question whether could billion note billion manag note thought type potenti
thought could get billion reason time didnt want jinx make forecast billion
manag see potenti beyond glucos beyond diabet well
alinitydriv ing growth manag commentari call still point alin long-term driver growth mani
year come
 anot need manag indic alway look doesnt feel right need someth
manag see someth think add suffici valu make worth invest manag reiter mani
organ growth opportun invest behind
full note feel free reach comment question
report result anoth strong quarter ep guidanc rang reflect doubl digit grow th
sale ere organ basi ith four unit exceed expect past year quarterli organ sale
grow th averag importantli abbott ell-posit ith portfolio new product pipelin
type strong grow th go forw ard
base perform momentum rais full year outlook forecast ep reflect nearli midpoint
report basi faster exclud fx
achiev broad-bas grow th across portfolio highlight area
freestyl libr achiev sale continu add significantli user base organ grow th
clinic benefit price ensur afford invest capac ave next sever month
follow ed cadenc increment capac
structur heart achiev mid-teen grow th led mitraclip hich grow th quarter
grow th us us approv devic ith enhanc featur clip size abbott
build posit structur heart decad deep pipelin tendyn cephea mitral
program tri-clip system tricuspid repair amplatz amulet left atrial appendag devic ith adopt
mitraclip under-penetrated market pipelin technolog abbott structur heart ell posit year
diagnost abbott focus global roll alin make great progress ith immunoassay clinic
chemistri test system europ earli stage launch hematolog molecular eu make progress
menu us fda approv alin blood plasma screen ith global roll-out alin posit
summari four busi exceed expect grow th strong acceler sustain abbott strateg
posit attract area healthcar key platform deliv impress result
today ad hat alreadi strong grow th forecast rais outlook year
refer growth rate organ basi unless note
organ sale
medic devic sale ith doubl digit grow th electrophysiolog heart failur structur heart diabet
nutrit led adult nutrit
establish pharmaceut ith grow th key emerg market
diagnost sale led lab grow th high singl digit sequenti improv point care rapid
fx impact hich approxim
 detail gross margin adjust sg sale
tax rate low er previou guidanc around due implement us tax reform tax rate align
revis full year forecast
expect organ barclay note previou guidanc
base current rate fx expect neg impact full year sale line ith expect impact
begin year
gross margin expect littl less modestli low er prior forecast barclay note
somewhat hich reflect temporari effect invest ramp market adopt alin ell
invest libr capac expans
 expect less sale
sg expect around sale
forecast adjust tax rate expect barclay note previous around
expect adjust ep reflect strong doubl digit grow th
expect organ sale grow th current rate fx headw ind
divis expect establish pharma grow mid-to-high singl digit nutrit grow mid-singl digit legaci diagnost
molecular point care grow high-singl digit ith rapid diagnost grow th low -to-mid singl digit
medic devic expect grow high singl digit ith continu double-digit grow th sever area
 expect gross margin littl less around sg around sale
 question manag respons verbatim arrang topic
question manag success
manag team hire devic mile long term plan anticip time ant robert ford stay
top medic devic busi respons on-board st jude ent ith st jude
reorgan busi align abbott like run busi abbott like fulli integr busi
 ith aler busi full integr gener manag ad number gener manag ent
manag transit there gener chang happen lot peopl part mile team longer
time think ith grow th look talent experi manag team look
forw ard decad robust grow th thu need replac evp role ent outsid sourc lisa earnhardt ho
bring great experi energi level ent bit organiz chang smaller unit give
focu gone smoothli ell read robert ho expect key leadership role
compani long time read betw een line one import thing hen leav compani
one notic smooth leadership transit isnt mile key leadership team read
abbott prepar continu leadership ith speed bump ill give time frame think peopl
 orri robert ith team year bring job experi perspect everyth
 ould look compani
question libr
diabet confid around icgm approv investor worri lack libr approv
trend bgm tell us libr adopt shouldnt concern isnt yet approv manag confid
 ill approv expect get hat appli abbott file icgm standard special control
clear transpar relat accuraci alarm shut etc manag note ouldnt file thought ould
fell short level abbott behind abbott timelin go specul exact date expect approv
libr expect given capac expans think billion product last quarter got question
 hether get billion get question billion think type potenti think
get billion reason time ye manag think grow th rate reflect size
market need afford product afford util access make mass market product
nich dont ant jinx make forecast billion think potenti beyond glucos analyt time
categori beyond diabet there beyond
think misunderstood libr today hen ent asnt get accur read interstiti fluid
navig hich accur challeng ith libr cost effect get
accur read cost posit core libr navig technolog asnt question outcom ere right
enough outcom ere sensor base glucos monitor mass scale hat ent
year ago lot discuss accuraci level level accuraci import goal make
mass avail low er price point isnt impli miss someth thing compar expens
high cost abbott manufactur sophist havent compromis profit profil gross margin
rise that ith heavi capit invest produc volum need product design afford
access sure devic commun realli understand stage capac everi day ad capac abbott ill
capac constrain opportun earabl market afford technolog
question sale growth outlook
acceler think middl upper end rang get guidanc abbott
see strength grow th driver abbott lot launch go across board go open capac
new manufactur supplement libr alin system roll mitraclip pick momentum lot busi
unsatisfi time time see sequenti improv never quit satisfi ith cardiac
rhythm manag stent neuromodul point care diagnost rapid diagnost busi show ing
sequenti sale grow th improv hich hat plan hat compani ork base strength across
board manag feel comfort grow th rate top line sort see rang manag
note challeng team hether temporari quarter half year hether feel fairli
sustain feel comfort sustain good ith earn step ep
second half feel good number say abbott never fall short bottom line right
 hat get high end rang manag comment think isnt good enough pretti healthi
grow th rate ith breadth product launch rollout alw ay challeng somew orld abbott
seem pretti ell across board area manag think that pretti good invest
question mitraclip
mitraclip statu reimburs updat timelin trend rate approv saw great quarter global sale
driven us major grow th us increas product new account continu invest clinic
field expans doubl digit quarter japan believ signific opportun longer term
build capabl europ rebound team good job put context conflict trial penetr
still low lot coordin go ith physician societi expect ncd open pretti soon anticip
get process around year end earli next year seen dozen privat commerci insur compani
alreadi reflect new indic largest segment medicar good see traction privat
question alin
alin statu updat launch eu us six differ system alin famili immunoassay clinic
chemistri europ one farthest along process menu expans unit state run fast
europ go ell system place measur deal close measur test record
 hen account run process go ell ill begin pick momentum us get menu breadth
china alin blood plasma screen blood suppli screen abbott close start japanes red
cross convert competitor hematolog launch earli stage molecular earli stage hy ill slow er
move launch ith year momentum take year convert exist base add account ere
busi inning time dont base inning time occasion account run
heavi duti price cut feel like offer competit show rate
sustain medic devic growth innov hat drive grow th overtim case differ busi
differ state believ still lot opportun stark felt strongli pipelin
appreci grow th rate high singl digit street didnt appreci believ time
right perform level ith new product ith medic devic keep innov new space
libr uniqu approach mass market diabet split type type libr enorm medic
devic opportun address invest manufactur go mass market sustain driven innov
abil go market afford level pleas see sequenti increment improv slow er
grow th matur busi think busi capabl low mid-singl digit grow th could take busi flat
that big bump grow th alw ay go new product disproportion drive overal grow th one advantag
mani busi devic arena there alw ay go somew that grow ing ay place
 innov futur
nutrit busi updat franchis sequenti improv nurtirion busi pleas ith
perform continu see soft market sever countri abbott made lot enhanc chang peopl
strategi enhanc competit year new product execut see manag think sustain
execut ell abbott see market rang compani alw ay strive someth
 seen quarter ith kind grow th good execut adult busi specif come asia
ou busi littl adult us nutrit that lot new product innov net format expans
market like vietnam place good stronghold there lot opportun grow th put
lot attent histor us china got attent
neuromodul what recoveri pathway saw improv ant complet sale forc
expans there disrupt occur complet focus improv product
sale team saw data point expect improv go year product
innov life cycl realli havent launch space start see invest output
new product ill give sale team thing ork ith
think balanc invest versu drop great thing abbott lot invest
deploy capit view ed import pay dow debt paid dow debt go billion point
abbott comfort posit strateg flexibl doesnt mean go use capit plant expans
alin libr expans mitraclip lot grow th happen opportun capit
use debt ill continu pay dow debt ill prudent hether right debt right time maintain healthi
strong dividend given pe tri get yield rate dividend investor difficult abbott ill continu
grow dividend recent alw ay prudent buy back share given return time matter return
matter etc option ye probabl ont get carri aw ay ere abl grow return cash
sharehold number differ ay return good return sharehold alw ay option present
abbott lot thing abbott doesnt feel right need someth
manag see someth think add suffici valu make orth invest mani organ grow th
opportun continu monitor team alw ay track opportun busi front burner right
small acquisit germani that adjunct diagnost autom much grow th potenti
opportun thing like valuabl abbott abbott much grow th potenti opportun
devic diagnost even nutrit pharma hunt real hard front expens side tri
balanc appetit investor grow ing earn invest busi alw ay tri find right balanc
much spend support grow th
tax rate process current rate sustain alw ay set tax rate think
sustain ould call sustain rate go forw ard
kristen stew art cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens
 ill directli indirectli relat specif recommend view express research report
barclay capit inc and/or one affili seek busi ith compani cover research report
result investor aw firm may conflict interest could affect object report investor
consid report singl factor make invest decis
barclay research produc invest bank barclay bank plc affili collect individu
barclay author contribut research report research analyst unless otherw ise indic public date
top report reflect local time report produc may differ releas date provid gmt
avail disclosur
 compani subject research report current import disclosur regard compani pleas
refer http //publicresearch barclay com altern send ritten request barclay research complianc seventh
avenu floor new york ny call
analyst respons prepar research report receiv compens base upon variou factor includ
firm total revenu portion hich gener invest bank activ profit revenu market
busi potenti interest firm invest client research ith respect asset class cover analyst
analyst regularli conduct site visit view materi oper cover compani barclay polici prohibit
accept payment reimburs cover compani travel expens visit
barclay research depart produc variou type research includ limit fundament analysi equity-link
analysi quantit analysi trade idea recommend contain one type barclay research may differ
contain type barclay research hether result differ time horizon methodolog otherw ise
order access barclay statement regard research dissemin polici procedur pleas refer
http //publicresearch barcap com/s/rd htm order access barclay research conflict manag polici statement pleas
refer http //publicresearch barcap com/s/cm htm
